QS50:F:F-STRAUM.HLD.UNSP.ADR/1/10 (EUR)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 13.1

Change

0.00 (0.00)%

Market Cap

USD 23.41B

Volume

500.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Straumann Holding AG provides tooth replacement and orthodontic solutions worldwide. It researches, develops, manufactures, and supplies dental implants, instruments, CADCAM prosthetics, orthodontic aligners, biomaterials, and digital solutions for use in tooth correction, replacement, and restoration, as well as to prevent tooth loss. The company offers dental implants and components made from titanium, titanium alloy, and ceramics; prosthetic elements made od ceramics, metal or polymer; and clear aligners. In addition, it offers resins for 3D printing and thermoplastics for clear aligner production; and biomaterials for tissue generation. Further, it provides digital equipment comprising scanners, milling machines and 3D printers. Further, it offers training and education services. The company provides its products to general dentists, specialists, and dental technicians and laboratories, as well as customers, such as distributors, hospitals, universities, and dental service organizations in approximately 100 countries through a network of distribution subsidiaries and partners. Straumann Holding AG was founded in 1954 and is headquartered in Basel, Switzerland.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-29 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
IUI1:F Intuitive Surgical Inc

N/A

USD 152.52B
ESL:F EssilorLuxottica Société ano..

N/A

USD 97.14B
ESLC:F ESSILORLUXOTTICA 1/2/O.N.

N/A

USD 96.96B
BOX:F Becton Dickinson and Company

N/A

USD 60.55B
HYB:F HOYA Corporation

N/A

USD 44.70B
HYB0:F HOYA CORP. ADR/ 1 O.N.

N/A

USD 43.06B
RMEA:F Resmed Inc DRC

N/A

USD 32.25B
RME:F ResMed Inc

N/A

USD 31.88B
CBH:F COLOPLAST SP.ADR 1/10 DK1

N/A

USD 26.54B
CBHD:F Coloplast A/S

N/A

USD 26.34B

ETFs Containing QS50:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -5.07% 55% F 41% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.07% 55% F 41% F
Trailing 12 Months  
Capital Gain 14.91% 72% C 62% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.91% 72% C 62% D
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -0.59% N/A N/A 43% F
Dividend Return -0.42% N/A N/A 38% F
Total Return 0.17% N/A N/A 7% C-
Risk Return Profile  
Volatility (Standard Deviation) 9.58% N/A N/A 89% A-
Risk Adjusted Return -4.40% N/A N/A 37% F
Market Capitalization 23.41B 89% A- 92% A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.